Literature DB >> 22372373

Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience.

Sujith Samarasinghe1, Colin Steward, Prashant Hiwarkar, Muhammad Ameer Saif, Rachael Hough, David Webb, Alice Norton, Sarah Lawson, Amrana Qureshi, Philip Connor, Peter Carey, Rod Skinner, Ajay Vora, Maria Pelidis, Brenda Gibson, Graham Stewart, Steve Keogh, Nick Goulden, Denise Bonney, Mathew Stubbs, Persis Amrolia, Kanchan Rao, Stefan Meyer, Rob Wynn, Paul Veys.   

Abstract

We retrospectively analysed the outcome of consecutive children with idiopathic severe aplastic anaemia in the United Kingdom who received immunosuppressive therapy (IST) or matched unrelated donor (MUD) haematopoietic stem cell transplantation (HSCT). The 6-month cumulative response rate following rabbit antithymocyte globulin (ATG)/ciclosporin (IST) was 32·5% (95% CI 19·3-46·6) (n = 43). The 5-year estimated failure-free survival (FFS) following IST was 13·3% (95% confidence interval [CI] 4·0-27·8). In contrast, in 44 successive children who received a 10-antigen (HLA-A, -B, -C, -DRB1, -DQB1) MUD HSCT there was an excellent estimated 5-year FFS of 95·01% (95% CI 81·38-98·74). Forty of these children had failed IST previously. HSCT conditioning was a fludarabine, cyclophosphamide and alemtuzumab (FCC) regimen and did not include radiotherapy. There were no cases of graft failure. Median donor chimerism was 100% (range 88-100%). A conditioning regimen, such as FCC that avoids total body irradiation is ideally suited in children. Our data suggest that MUD HSCT following IST failure offers an excellent outcome and furthermore, if a suitable MUD can be found quickly, MUD HSCT may be a reasonable alternative to IST.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22372373     DOI: 10.1111/j.1365-2141.2012.09066.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  36 in total

1.  Excellent outcome with a high proportion of mixed chimerism in patients with severe aplastic anemia treated with partially T-cell-depleted peripheral hematopoietic stem cell transplants.

Authors:  S Masouridi-Levrat; F Simonetta; Y Beauverd; O Tsopra; Y Tirefort; C Stephan; E Levrat; M Ansari; F Verholen; E Roosnek; J R Passweg; Y Chalandon
Journal:  Bone Marrow Transplant       Date:  2016-02-08       Impact factor: 5.483

Review 2.  The diagnosis and treatment of aplastic anemia: a review.

Authors:  Maurizio Miano; Carlo Dufour
Journal:  Int J Hematol       Date:  2015-04-03       Impact factor: 2.490

Review 3.  Alternative donor transplant of benign primary hematologic disorders.

Authors:  J Tolar; P Sodani; H Symons
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

4.  Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society of Bone Marrow Transplantation and Cell Therapies and the EBMT Severe Aplastic Anemia Working Party.

Authors:  Raynier Devillier; Jean-Hugues Dalle; Austin Kulasekararaj; Maud D'aveni; Laurence Clément; Alicja Chybicka; Stéphane Vigouroux; Patrice Chevallier; Mickey Koh; Yves Bertrand; Mauricette Michallet; Marco Zecca; Ibrahim Yakoub-Agha; Jean-Yves Cahn; Per Ljungman; Marc Bernard; Pascale Loiseau; Valérie Dubois; Sébastien Maury; Gérard Socié; Carlo Dufour; Regis Peffault de Latour
Journal:  Haematologica       Date:  2016-04-07       Impact factor: 9.941

5.  Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia.

Authors:  Michael J Eckrich; Kwang-Woo Ahn; Richard E Champlin; Peter Coccia; Kamar Godder; John Horan; David Margolis; H Joachim Deeg; Mary Eapen
Journal:  Am J Hematol       Date:  2013-11-15       Impact factor: 10.047

Review 6.  Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders.

Authors:  Shalini Shenoy; Jaap J Boelens
Journal:  Curr Opin Pediatr       Date:  2015-02       Impact factor: 2.856

7.  Diagnosis and treatment of pediatric acquired aplastic anemia (AAA): an initial survey of the North American Pediatric Aplastic Anemia Consortium (NAPAAC).

Authors:  David A Williams; Carolyn Bennett; Alison Bertuch; Monica Bessler; Thomas Coates; Seth Corey; Yigal Dror; James Huang; Jeffrey Lipton; Timothy S Olson; Ulrike M Reiss; Zora R Rogers; Colin Sieff; Adrianna Vlachos; Kelly Walkovich; Winfred Wang; Akiko Shimamura
Journal:  Pediatr Blood Cancer       Date:  2013-11-27       Impact factor: 3.167

8.  Immunosuppressive therapy versus alternative donor hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched familial donor.

Authors:  Y B Choi; E S Yi; J W Lee; K W Sung; H H Koo; K H Yoo
Journal:  Bone Marrow Transplant       Date:  2016-09-26       Impact factor: 5.483

Review 9.  Aplastic Anemia.

Authors:  Neal S Young
Journal:  N Engl J Med       Date:  2018-10-25       Impact factor: 91.245

Review 10.  Preventing stem cell transplantation-associated viral infections using T-cell therapy.

Authors:  Ifigeneia Tzannou; Ann M Leen
Journal:  Immunotherapy       Date:  2015-08-07       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.